Andrew R. Weintraub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andrew R. Weintraub has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abhishek Chatterjee
Division of Plastic and Reconstructive Surgery, Department of Surgery, Tufts Medical Center, Boston, Massachusetts; Division of Surgical Oncology, Department of Surgery, Tufts Medical Center, Boston, Massachusetts
1 shared publication Alison Massed
CardioVascular Center, Tufts Medical Center, Boston, Massachusetts
1 shared publication- Antonis Stavros Manolis
First Department of Cardiology, Athens University School of Medicine, Athens, Greece
1 shared publication - Ayan R. Patel
CardioVascular Center, Tufts Medical Center , Boston, MA
1 shared publication - Benjamin Koethe
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center , Boston, MA
1 shared publication - Benjamin S. Wessler
Tufts Clinical and Translational Science Institute, Tufts Medical Center, Tufts University , Boston, MA
1 shared publication
Latest Publications
- 22 January 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (5) , 475-482
Cost Utility of Transcatheter Aortic Valve Replacement: Sapien 3 Versus CoreValve Evolut R
Transcatheter aortic valve replacement (TAVR) has become the preferred treatment for severe aortic stenosis. Previous studies compare clinical outcomes of leading TAVR valves, but there is no evidence of cost-utility comparison, leaving a clinical information gap when selecting valves. Here we share a cost-utility analysis comparing the Sapien 3 (S3) (Edwards Lifesciences, Irvine, CA) and CoreValve Evolut R (ER) (Medtronic, Dublin, IR) across five clinical endpoints. Utility scores from patient surveys and clinical outcomes from the literature were used to estimate quality-adjusted life years (QALYs) associated with successful procedure and postoperative complications for S3 and ER. A decision tree was constructed with rollback analysis to highlight the more cost-effective strategy. An incremental cost-utility ratio (ICUR) analysis was performed with a willingness to pay at $50,000. Deterministic and probabilistic sensitivity analyses were performed to validate robustness of results and account for uncertainty. S3 was found to be more costly ($68,377 vs. $66,072), but more effective (1.87 vs. 1.66) compared with ER. An ICUR of 11,288.12 favored S3, making it the more cost-effective option with a moderate confidence of 73.68% in Monte Carlo analysis. Cost-utility analysis can be used to aid in healthcare economics decision-making when selecting between comparable technologies used for TAVR procedures.
- 22 January 2023
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 69 (5) , 475-482
Cost Utility of Transcatheter Aortic Valve Replacement: Sapien 3 Versus CoreValve Evolut R
Transcatheter aortic valve replacement (TAVR) has become the preferred treatment for severe aortic stenosis. Previous studies compare clinical outcomes of leading TAVR valves, but there is no evidence of cost-utility comparison, leaving a clinical information gap when selecting valves. Here we share a cost-utility analysis comparing the Sapien 3 (S3) (Edwards Lifesciences, Irvine, CA) and CoreValve Evolut R (ER) (Medtronic, Dublin, IR) across five clinical endpoints. Utility scores from patient surveys and clinical outcomes from the literature were used to estimate quality-adjusted life years (QALYs) associated with successful procedure and postoperative complications for S3 and ER. A decision tree was constructed with rollback analysis to highlight the more cost-effective strategy. An incremental cost-utility ratio (ICUR) analysis was performed with a willingness to pay at $50,000. Deterministic and probabilistic sensitivity analyses were performed to validate robustness of results and account for uncertainty. S3 was found to be more costly ($68,377 vs. $66,072), but more effective (1.87 vs. 1.66) compared with ER. An ICUR of 11,288.12 favored S3, making it the more cost-effective option with a moderate confidence of 73.68% in Monte Carlo analysis. Cost-utility analysis can be used to aid in healthcare economics decision-making when selecting between comparable technologies used for TAVR procedures.
- Open Access
- 1 September 2020
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 33 (12) , 1528-1531
Paradoxical Low-Flow Low-Gradient Aortic Stenosis: Effect of Low Transvalvular Flow Conditions on Indexed Stroke Volume after Transcatheter Aortic Valve Replacement
- 1 September 2020
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 33 (12) , 1528-1531
Open AccessParadoxical Low-Flow Low-Gradient Aortic Stenosis: Effect of Low Transvalvular Flow Conditions on Indexed Stroke Volume after Transcatheter Aortic Valve Replacement
- 1 October 1990
- Published by Elsevier in The American Journal of Cardiology
- Vol. 66 (12) , 947-953
Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease
- 1 October 1990
- Published by Elsevier in The American Journal of Cardiology
- Vol. 66 (12) , 947-953
Electrophysiologic and electrocardiographic effects, efficacy and safety of encainide in malignant ventricular arrhythmias associated with coronary artery disease